TMPRSS2 and COVID-19: Considering that a low expression of TMPRSS2 is significantly associated with a short overall survival in LUAD, low TMPRSS2 expression may result in severity and death of LUAD cancer patients infected with COVID-19 or SARS-CoV-2.